Clinical Trial: Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Brief Summary: This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.
Detailed Summary:
Sponsor: Bayer
Current Primary Outcome: Types of cIAI infections [ Time Frame: Day 1 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Cure rate [ Time Frame: 5-14 days ]
- Clinical signs and symptoms [ Time Frame: 5-14 days ]
- Duration until improvement and cure [ Time Frame: 5-14 days ]
- Adverse event collection [ Time Frame: 5-14 days ]
Original Secondary Outcome: Same as current
Information By: Bayer
Dates:
Date Received: March 11, 2010
Date Started: December 2009
Date Completion:
Last Updated: June 20, 2013
Last Verified: June 2013
